EGFR T790M Resistance Mutation in NSCLC: Real-Life Data of Austrian Patients Treated with Osimertinib

被引：2

作者：

Hochmair, Maximilian ^{[1
]}

Holzer, Sophia ^{[1
]}

Filipits, Martin ^{[2
]}

Mohn-Staudner, Andrea ^{[1
]}

Errhalt, Peter ^{[3
]}

Absenger, Gudrun ^{[4
]}

Bundalo, Tatjana ^{[5
]}

Arns, Madeleine ^{[1
]}

Setinek, Ulrike ^{[1
]}

Mikes, Romana ^{[6
]}

Kolb, Rainer ^{[7
]}

Schumacher, Michael ^{[8
]}

Zoechbauer-Mueller, Sabine ^{[2
]}

Patocka, Kurt ^{[9
]}

Haslbauer, Ferdinand ^{[10
]}

Rudzki, Jakob ^{[11
]}

Burghuber, Otto ^{[1
]}

机构：

[1] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[2] Med Univ Vienna, Dept Med 1, Vienna, Austria

[3] Med Univ Vienna, Dept Pneumol, Krems, Austria

[4] Med Univ Graz, Div Clin Oncol, Dept Med, Graz, Austria

[5] Landeskrankenhaus Hochegg, Dept Pneumol, Grimmenstein, Austria

[6] Univ Clin Salzburg, Dept Pulm Med, Salzburg, Austria

[7] Klinikum Wels Grieskirchen, Dept Pulm Med, Wels, Austria

[8] Hosp Elisabethinen, Dept Pneumol, Linz, Austria

[9] Krankenhaus Hietzing, Dept Pneumol, Vienna, Austria

[10] Salzkammergut Klinikum Vocklabruck, Dept Internal Med, Vocklabruck, Austria

[11] Med Univ Innsbruck, Dept Hematol & Oncol, Innsbruck, Austria

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

T790M; osimertinib; TKI resistance; Liquid Biopsy Re-biopsy;

D O I：

10.1016/j.jtho.2016.11.1769

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02b-101

引用

页码：S1254 / S1254

页数：1

共 50 条

[1] EGFR T790M resistance mutation in NSCLC: Real-life data of Austrian patients treated with osimertinib
Holzer, Sophia
Hochmair, Maximilian
Filipits, Martin
Mohn-Staudner, Andrea
Errhalt, Peter
Absenger, Gudrun
Bundalo, Tatjana
Arns, Britt-Madelaine
Setinek, Ulrike
Mikes, Romana
Kolb, Rainer
Schumacher, Michael
Zoechbauer-Mueller, Sabine
Patocka, Kurt
Haslbauer, Ferdinand
Rudzki, Jakob
Burghuber, Otto Chris
WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 (19-20) : 769 - 770
[2] EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.
Hochmair, Maximilian J.
Holzer, Sophia
Filipits, Martin
Mohn-Staudner, Andrea
Arns, Madeleine
Errhalt, Peter
Absenger, Gudrun
Koller-Herzog, Ursula
Setinek, Ulrike
Haslbauer, Ferdinand
Korger, Mark A.
Patocka, Kurt
Kolb, Rainer
Burghuber, Otto
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[3] EGFR resistant T790M mutation in NSCLC: real-life data of patients treated with AZD9291
Hochmair, M.
Holzer, S.
Setinek, U.
Filipits, M.
Mohn-Staudner, A.
Korger, M.
Fabikan, H.
Pirker, C.
Burghuber, O. C.
WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 (19-20) : 831 - 831
[4] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
Zhao, S.
Jiang, T.
Li, X.
Zhao, C.
Su, C.
Ren, S.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
[5] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
Luo, Yung-Hung
Liu, Han
Wampfler, Jason A.
Tazelaar, Henry D.
Li, Yalun
Peikert, Tobias
Liu, Dan
Leventakos, Konstantinos
Chen, Yuh-Min
Yang, Yanan
Chiou, Shih-Hwa
Yang, Ping
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2099 - 2114
[6] Real-Life Data of Osimertinib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Alfaro Autor, C.
Romero, A.
Calvo De Juan, V.
Franco, F.
Sanchez Romero, E.
Ortiz Cortes, N.
Sanz Moreno, S.
Rodriguez Festa, A.
Serna Blasco, R.
Barquin Del Romo, M.
Provencio, M.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1036 - S1036
[7] Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
Zhang, X.
Wu, Y-L.
Chen, Y.
Zhang, H.
Wu, G.
Lu, Y.
Liang, Z.
Hu, Y.
Cheng, Y.
Wang, J.
Ying, J.
Liu, W.
Liang, Z.
ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1537
[8] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
Yung-Hung Luo
Han Liu
Jason A. Wampfler
Henry D. Tazelaar
Yalun Li
Tobias Peikert
Dan Liu
Konstantinos Leventakos
Yuh-Min Chen
Yanan Yang
Shih-Hwa Chiou
Ping Yang
Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2099 - 2114
[9] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
Zhao, Sha
Li, Xuefei
Zhao, Chao
Jiang, Tao
Jia, Yijun
Shi, Jinpeng
He, Yayi
Li, Jiayu
Zhou, Fei
Gao, Guanghui
Li, Wei
Chen, Xiaoxia
Su, Chunxia
Ren, Shengxiang
Zhou, Caicun
LUNG CANCER, 2019, 128 : 33 - 39
[10] Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid
Theoleyre, Sandrine
Masson, Ingrid
Herbreteau, Guillaume
Vallee, Audrey
Senellart, Helene
Denis, Marc G.
LUNG CANCER, 2017, 114 : 111 - 112

← 1 2 3 4 5 →